EQS-News: Rentschler implements innovative learning program in collaboration with MassBioEd and WPI 07.12.2022, 15:00 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Rentschler Biopharma SE / Key word(s): Alliance
Rentschler implements innovative learning program in collaboration with MassBioEd and WPI

07.12.2022 / 15:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Rentschler implements innovative learning program in collaboration with MassBioEd and WPI 

  • Program trains people returning to the workforce for biotech manufacturing positions

Laupheim, Germany and Milford, MA, USA, December 07, 2022 – Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, is celebrating its 150th anniversary this year, and the company continues to evolve and grow.  Adjacent to its existing facility in Milford, MA, the company has undertaken the largest expansion in its long history. The state-of-the-art Rentschler Biopharma Manufacturing Center (RBMC) will add 22,000 square feet of manufacturing cleanroom space and house four new 2,000 L single-use bioreactors, in addition to being highly automated and leveraging industry 4.0 solutions.  As the company grows in terms of capacity, technology, projects, and clients, it is also growing its highly trained workforce.

Earlier this year, the company kicked off an exciting program with MassBioEd and Worcester Polytechnic Institute (WPI) to train people re-joining the workforce for stable, attractive biotech manufacturing opportunities. MassBioEd’s Life Sciences Apprenticeship Program is building talent pipelines for positions like Biomanufacturing Technicians, providing individuals with non-traditional training opportunities to enter careers in the life sciences. Rentschler Biopharma joined as one of the first employer partners for the expansion of the program into Central Massachusetts. The inaugural group of ten (10) apprentices has completed 16 weeks of training: Eight weeks involved a MassBio-led curriculum including basic academic coursework, as well as an introduction to business and to biotech. The additional eight weeks were spent at WPI Biomanufacturing Education and Training Center (BETC) to learn the fundamentals of biotech production, including both upstream and downstream processes. Five of the apprentices started at Rentschler Biopharma in September, and the remaining five at the end of November.

Mark Caswell, Vice President, Site Head, Rentschler Biopharma, Inc., said: “Rentschler Biopharma has remained relevant throughout its history by creating value sustainably for our employees and clients. We focus on anticipating the needs of tomorrow with highly trained and experienced people. The workforce training program we have undertaken with WPI and MassBioEd is truly a win-win situation, enabling people from underrepresented communities to enter careers in the biotech space while supporting our need to bring in new talent.”

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,200 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.

For further information, please visit http://www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn and Facebook.

Contact:
Rentschler Biopharma SE

Dr. Cora Kaiser
Senior Director Corporate Communication
Phone: +49-7392-701-874
communications@rentschler-biopharma.com

Media inquiries:

MC Services AG
Eva Bauer
Phone: +49-89-210228-0         
rentschler@mc-services.eu
U.S.
Laurie Doyle
Phone: +1-339-832-0752


07.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


1507305  07.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1507305&application_name=news&site_id=boersennews
Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News

Gestern 22:29 Uhr • Artikel • dpa-AFX

Gestern 22:18 Uhr • Artikel • dpa-AFX

Gestern 21:01 Uhr • Artikel • dpa-AFX

Gestern 20:53 Uhr • Artikel • dpa-AFX

Gestern 20:40 Uhr • Artikel • dpa-AFX

Gestern 20:25 Uhr • Artikel • dpa-AFX

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer